FDA approves intravenous version of J&J’s Uptravi to prevent treatment interruptionsnews2021-08-03T13:32:31+00:00August 3rd, 2021|Fierce Pharma|
Eli Lilly’s COVID-19 antibody sales crater as variants, vaccines take a tollnews2021-08-03T13:25:33+00:00August 3rd, 2021|Fierce Pharma|
BeiGene lays plans for ‘flagship’ biologics plant and R&D center in New Jerseynews2021-08-03T12:36:18+00:00August 3rd, 2021|Fierce Pharma|
Bristol Myers pulls an Istodax lymphoma use 10 years after FDA accelerated approvalnews2021-08-03T10:15:46+00:00August 3rd, 2021|Fierce Pharma|
AstraZeneca’s launch plan for first-in-class lupus med Saphnelo centers on patient-designed support programnews2021-08-03T00:29:26+00:00August 3rd, 2021|Fierce Pharma|
Takeda still on the hook for €398M tax linked to distant AbbVie-Shire breakup feenews2021-08-02T15:20:59+00:00August 2nd, 2021|Fierce Pharma|
FTC drops antitrust case against AbbVie, but still decries the company’s ‘ill-gotten gains’news2021-08-02T15:14:53+00:00August 2nd, 2021|Fierce Pharma|
J&J notches a win in $50M talc lawsuit, but tens of thousands still pendingnews2021-08-02T14:46:32+00:00August 2nd, 2021|Fierce Pharma|
Servier scores a win in bid to expand Tibsovo in acute myeloid leukemia—and reach Europe where Agios failednews2021-08-02T14:00:33+00:00August 2nd, 2021|Fierce Pharma|
Pfizer, Moderna hike COVID-19 vaccine prices in new European supply deals: reportnews2021-08-02T13:34:32+00:00August 2nd, 2021|Fierce Pharma|
